Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

NCT06564584 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertriglyceridemia
Nonalcoholic Fatty Liver Disease

Interventions

DRUG: TLC-2716 Dose 1
DRUG: TLC-2716 Dose 2
DRUG: Placebo

Sponsor

OrsoBio, Inc